Mugweru Julius, Liu Jianxiong, Makafe Gaelle, Chiwala Gift, Wang Bangxing, Wang Changwei, Li Xinjie, Tan Yaoju, Yew Wing Wai, Tan Shouyong, Zhang Tianyu
State Key Laboratory of Respiratory Disease, Guangzhou Regenerative Medicine and Health Guangdong Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences (CAS), Guangzhou, China.
University of Chinese Academy of Sciences, Beijing, China.
Infect Drug Resist. 2018 Jun 13;11:891-894. doi: 10.2147/IDR.S163965. eCollection 2018.
Ethionamide (ETA) and prothionamide (PRO) are interchangeably used in tuberculosis (TB) chemotherapy regimens. Subtle discrepancies between biochemical and genetic information on the modes of sensitivity and resistance of isoniazid (INH) and ETA warrants further studies. We report a new mutation - EthA - in Bacillus Calmette-Guérin that corresponds with co-resistance to both PRO and ETA, which to the best of our knowledge has not been reported before. Our findings suggest that mutation EthA could be used as a marker site for testing PRO and ETA cross-resistance.
乙硫异烟胺（ETA）和丙硫异烟胺（PRO）在结核病化疗方案中可交替使用。关于异烟肼（INH）和ETA敏感性和耐药性模式的生化和遗传信息之间的细微差异值得进一步研究。我们报告了卡介苗中的一种新突变——EthA，它与对PRO和ETA的共同耐药性相对应，据我们所知，此前尚未有过相关报道。我们的研究结果表明，突变EthA可作为检测PRO和ETA交叉耐药性的标记位点。
